ERBB2 and neoplasm: Preceding analyses of the implementation of guideline recommendations in the study sample revealed that the proportion of patients (with available information on HER2/neu expression of their tumor) who received trastuzumab rose from 2 to 47% between 2000 and 2009 [48].